The total diagnosed NMIBC prevalence in the 7MM (the United States, EU5 (the United Kingdom, Germany, Spain, Italy, and France), and Japan) in 2017 was 533,263 cases in 2017, which further is expected to increase in the forecast period 2020-30. As per Delveinsight, the Non-Muscle Invasive Bladder Cancer (NMIBC) Market is anticipated to surge with a CAGR of 8% during the study period 2017-2030.
The NMIBC Market is going to experience a significant boost in the coming years owing to several factors such as forthcoming launches, a boost in R&D, a better understanding of cancer, and many others.
Similarly, the increasing NMIBC prevalence is another key factor which is expected to drive the NMIBC Market forward in the coming years. While the healthcare costs associated with bladder cancer, and Intra- and inter-tumoral heterogeneity of PD-L1 expression and evolution of PD-L1 status with the development of treatment resistance is another factor restraining the growth of the NMIBC market size.
For more detailed information on NMIBC Market Drivers and Barriers, visit: https://www.delveinsight.com/blog/nmibc-market-drivers-and-barriers/